BerGenBio ASA

OSE:BGBIO.OL

0.152 (NOK) • At close November 17, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) NOK.

2024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Revenue 0.681000.1670.3540000.3890000.7740000.6010000.218008.6822.3350000000000
Cost of Revenue 000.10517.29716.7940.1090.0070.00700.140.3140.31700.3350.3350.3350000000000000000000
Gross Profit 0.6810-0.105-17.13-16.44-0.109-0.007-0.0070.389-0.14-0.314-0.3170.774-0.335-0.335-0.3350.6010000.218008.6822.3350000000000
Gross Profit Ratio 100-102.575-46.441000100010001000100110000000000
Reseach & Development Expenses 22.28311.4880.66123.42229.3579.7671.6972.8942.6541.4671.7622.4572.4142.5073.6744.1496.4135.3145.9434.1227.34941.31538.6843.8423.481002.1593.1623.09203.1093.2224.1060
General & Administrative Expenses 0000000000002.4142.5073.6744.1496.4135.3145.9434.1227.3496.0194.0153.8423.481002.1593.162003.1093.22200
Selling & Marketing Expenses 00000000000000000000000000000000000
SG&A 0032.3690.3181.60818.83126.0224.35927.82319.8231.7924.5982.4142.5073.6744.1496.4135.3145.9434.1227.3496.0194.0153.8423.481002.1593.162003.1093.22200
Other Expenses 11.92315.69818.731000069.52974.13960.96186.47576.10965.67968.91288.6379.26966.0116358.77552.11551.92247.53951.96550.65749.76438.11750.73252.62244.34933.4690.00162.680.0010.0010.001
Operating Expenses 34.20627.18651.76123.7443.89928.0947.76372.42376.79362.42888.23778.56668.09371.41992.30483.41872.42468.31464.71856.23759.27147.53951.96554.49953.24538.11750.73254.78147.51136.56133.84565.78928.03416.3466.464
Operating Income -33.525-27.186-50.76-40.87-43.544-28.09-47.762-72.423-76.404-62.428-88.238-78.566-67.321-71.419-92.306-83.419-71.822-68.314-64.718-56.237-59.051-47.539-51.965-45.818-50.909-38.116-50.735-54.781-47.511-36.561-33.846-65.789-28.034-16.341-66.464
Operating Income Ratio -49.22900-244.731-123.006000-196.411000-86.978000-119.504000-270.87600-5.277-21.8030000000000
Total Other Income Expenses Net 4.8962.3711.043.6461.9080.158-1.0740.425-0.7852.6314.168-2.501-1.4450.9213.4512.175-2.0460.99-2.5577.6741.4642.946-0.8221.507-0.1650.461.4941.001-0.1231.135-0.2360.7240.1340.9640.256
Income Before Tax -28.629-24.815-49.72-36.117-41.636-27.932-48.836-71.998-77.189-59.797-84.07-81.067-68.766-70.498-88.855-81.244-73.868-67.324-67.275-48.563-57.587-44.593-52.787-44.311-51.074-37.656-49.238-53.78-47.634-35.426-34.082-65.065-27.9-15.377-66.208
Income Before Tax Ratio -42.0400-216.269-117.616000-198.429000-88.845000-122.908000-264.16100-5.104-21.8730000000000
Income Tax Expense 0000.062-7.2024.0772.007-0.4250.785-2.631-4.1682.501-5.3673.0284.5684.368-12.4154.4783.5248.507-2.294.2261.5091.76-0.8020.9741.6221.045-1.7261.5960.5411.119-0.4341.1020.536
Net Income -28.629-24.815-49.72-36.117-41.636-27.932-48.836-71.573-77.974-57.166-79.902-83.568-68.766-70.498-88.855-81.244-73.868-67.324-67.275-48.563-57.587-44.593-52.787-44.311-51.074-37.656-49.238-53.78-47.634-35.426-34.082-65.065-27.9-15.377-66.208
Net Income Ratio -42.0400-216.269-117.616000-200.447000-88.845000-122.908000-264.16100-5.104-21.8730000000000
EPS -0.73-0.63-1.85-1.34-1.55-3.16-14.51-9.26-10.09-7.4-10.34-10.83-8.92-9.18-11.59-10.66-9.71-8.85-9.87-8.25-10.64-8.24-10.72-9.14-10.53-7.77-10.38-12.15-10.77-8.03-7.9-21.78-6.33-3.49-15.02
EPS Diluted -0.73-0.63-1.39-1.34-1.55-3.16-14.51-9.26-10.09-7.4-10.34-10.83-8.92-9.18-11.59-10.66-9.71-8.85-9.87-8.25-10.64-8.24-10.72-9.14-10.53-7.77-10.38-12.15-10.77-8.03-7.9-21.78-6.33-3.49-15.02
EBITDA -27.636-22.928-49.614-35.305-50.645-23.904-45.748-69.304-85.251-55.868-81.954-77.846-67.013-68.057-87.401-78.713-84.101-63.64-60.998-48.367-58.857-43.117-50.262-43.86-51.037-37.597-49.184-53.725-47.47-35.375-33.253-63.501-28.411-15.177-65.883
EBITDA Ratio -40.58100-211.407-143.065000-219.154000-86.58000-139.935000-269.98600-5.052-21.8570000000000